SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Video

Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Recent Videos
Related Content
Moderna Withdraws BLA For its Influenza COVID-19 Combination Vaccine

Moderna Withdraws BLA For its Influenza COVID-19 Combination Vaccine

John Parkinson
May 21st 2025
Article
From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

From Pathogen to Infectious Disease Diagnosis: Identifying a Novel Variant of Klebsiella Pneumoniae

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc ;Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS
December 23rd 2024
Podcast
FDA Approves Novavax COVID-19 Vaccine

FDA Approves Novavax COVID-19 Vaccine

John Parkinson
May 19th 2025
Article
From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
August 1st 2024
Podcast
RSV Prophylaxis: Palivizumab, Nirsevimab, and More

RSV Prophylaxis: Palivizumab, Nirsevimab, and More

Noah Christian, MD;Joseph M. Collaco, MD, PhD
May 9th 2025
Article
Influenza COVID-19 Combination Vaccine Induces Higher Immune Response Than Standalone Immunizations

Influenza COVID-19 Combination Vaccine Induces Higher Immune Response Than Standalone Immunizations

John Parkinson
May 7th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.